

Bioorganic & Medicinal Chemistry

Bioorganic & Medicinal Chemistry 16 (2008) 4431-4437

Synthesis and antibacterial activity of egonol derivatives

Safiye Emirdağ Öztürk, Yurdanur Akgül* and Hüseyin Anıl*

Ege University, Faculty of Science, Chemistry Department, 35100 Izmir, Turkey

Received 6 December 2007; revised 14 February 2008; accepted 19 February 2008

Available online 5 March 2008

Abstract—Synthesis of egonol derivatives, 5-(3"-chloropropyl)-7-methoxy-2-(3',4'-methylenedioxyphenyl)benzofuran 1, 5-(3"-bromopropyl)-7-methoxy-2-(3',4'-methylenedioxyphenyl)benzofuran 2, 3-[2-(1,3-benzodioxol-5-yl)-7-methoxy-1-benzofuran-5-yl]propanal 3, 5-(3"-iodopropyl)-7-methoxy-2-(3',4'-methylenedioxyphenyl)benzofuran 4, 5-[3-(3"-bromopropyloxy) propyl]-7-methoxy-2-(3',4'-methylenedioxyphenyl)benzofuran 5, 3-[2-(1,3-benzodioxol-5-yl)-7-methoxy-1-benzofuran-5-yl]propylmethanoate 6, 3-[2-(1,3-benzodioxol-5-yl)-7-methoxy-1-benzofuran-5-yl]propyloleate 7, 5-[3"-hydroxypropyl]-6-bromo-7-methoxy-2-(3', 4'-methylenedioxyphenyl)benzofuran 8, 4-[2-(1,3-benzodioxol-5-yl)-7-methoxy-1-benzofuran-5-yl]propylbenzoate 10, 5-[3"-hydroxypropyl]-7-methoxy-3-nitro-2-(3',4'-methylenedioxyphenyl)benzofuran 11 and their antibacterial activity against *Staphylococcus aureus*, *Bacillus subtilis*, *Candida albicans* and *Escherichia coli* are reported. The starting material egonol 5-[3"-(hydroxy)propyl]-7-methoxy-2-(3', 4'methylenedioxyphenyl)benzofuran was isolated from seeds of *Styrax officinalis* L. The structural elucidication of these compounds (1−11) was established using 1D (¹H, ¹³C), 2D NMR (HMBC, HMQC, COSY) and LCMS spectroscopic data. While egonol and some synthesised new compounds show similar antibacterial activity and MIC values against *S. aureus*, *B. subtilis*, *C. albicans* and *E. coli*, other new derivatives show different activity against *S. aureus*, *B. subtilis*, *C. albicans* and *E. coli*. © 2008 Elsevier Ltd. All rights reserved.

1. Introduction

Styrax officinalis L. is a member of the Styracaceae family, which is constituted of small trees and shrubs. It has been found from in Palestine to Italy. In Turkey, it grows mainly in north, south and western Anatolia. 4,10 Egonol is an aryl-benzofuran that contains a hydroxy group at C3", which was first isolated in 1915 by Okada from the seed oil of S. japonicum and was formulated by Kawai as 5-[3"-(hydroxy)propyl]-7-methoxy-2-(3',4'methylenedioxyphenyl)benzofuran. Seeds of the fruit of S. japonicum, S. obassia, S. formasanum, S. suberifolium and S. officinalis are known to contain various egonol derivatives. 1,2,11,5 Egonol and its derivatives obtained from the seeds of Styrax species has attracted the attention of synthetic organic chemists, as a result of its activity against human leukaemic cells⁸ in addition to anti-complement activity,3 cytotoxic activity9 and antifungal and antibacterial activity.6 Here we report the synthesis and biological activity of eleven new egonol derivatives (see Fig. 1).

Keywords: Styrax officinalis; Styracaceae; Styrax; Antibacterial activity; Egonol; Benzofurans.

2. Results and discussion

The synthetic pathway in the present work is outlined in Schemes 1 and 2. Egonol isolated from the seeds of *S. officinalis* L. was used as the main starting material. The major product of the reaction of egonol with *p*-toluenesulfonylchloride in the presence of a small amount of pyridine was 5-[3''-chloropropyl]-7-metoxy-2-(3',4'-methylenedioxyphenyl)benzofuran1 (Scheme 1). Its positive ion-mode LSMS/APCI showed molecular ion peaks at <math>m/z 347.1 and 345.1 [M]⁺ consistent with a molecular formula of $C_{19}H_{17}ClO_4$. The ¹H and ¹³C spectra of compound 1 exhibited peaks at δ 3.57 (H3'') and 44.46 (C3''). The corresponding signals for egonol were at δ 3.73 and 62.70.

Reaction of egonol with NaBr/H₂SO₄ in water:acetone under reflux gave compound **2** (Scheme 1), whose LCMS–APCI gave ion peaks at m/z 391.0 and 393.0 [M]⁺ suggesting a molecular formula of C₁₉H₁₇BrO₄. The ¹H NMR spectrum of compound **2** showed an H3" upfield chemical shift at $\delta_{\rm H}$ 3.43 instead of at $\delta_{\rm H}$ 3.73 in egonol (Table 1). On the basis of the above results, compound **2** was deduced to be 5-(3"-bromopropyl)-7-methoxy-2-(3',4'-methylenedioxyphenyl)benzofuran.

Compound 3 was obtained from an oxidation reaction of egonol using PCC in acetone-CH₂Cl₂ (Scheme 1).

^{*} Corresponding authors. Tel./fax: +90 232 3888264; e-mail addresses: yurdanur.akgul@ege.edu.tr; huseyin.anil@ege.edu.tr

Figure 1. Structure of egonol and its derivatives.

The 1H NMR spectrum of compound 3 indicated two methylenes ($\delta_{\rm H}$ 3.05, 2.85 instead of at $\delta_{\rm H}$ 1.97, 2.85 in egonol), six aromatic methynes ($\delta_{\rm H}$ 6.77, 6.96, 6.82, 7.32, 6.88, 7.41), one methylenedioxy ($\delta_{\rm H}$ 6.00), one methoxy (4.04) and one aldehyde signal ($\delta_{\rm H}$ 9.85). The main difference in the 1H NMR spectrum of compound 3 with that of egonol is the presence of the aldehyde proton signal at $\delta_{\rm H}$ 9.85 (1H, t) and the absence of a signal at $\delta_{\rm H}$ 3.73 (2H, t) in egonol. Therefore, the structure of 3 was established as 3-[2-(1,3-benzodioxol-5-yl)-7-methoxy-1-benzofuran-5-yl]propanal.

The product of the reaction of compound **1** with NaI was compound **4** (Scheme 2). 1 H and 13 C NMR analysis of compound **4** indicated the H3"/C3" upfield chemical shift at $\delta_{\rm H}$ 3.19/ $\delta_{\rm C}$ 6.72 instead of at $\delta_{\rm H}$ 3.57/ $\delta_{\rm C}$ 44.46

in compound **1**. Therefore, the structure of compound **4** was established as 5-(3"-iodopropyl)-7-methoxy-2-(3',4'-methylenedioxyphenyl)benzofuran.

Compound 5 was obtained from the reaction of egonol with 1,3-dibromopropane and K₂CO₃ in DMF (Scheme 1). The molecular formula of 5 was assigned to be C_{22} $H_{23}BrO_5$ from the ion peaks at m/z 449.1 [M]⁺ and 447.1 [M]⁺ in the LCMS/APCI. The ¹H NMR spectrum of compound 5 showed a total of 23 proton signals, which included six methylenes (δ_H 3.56, 3.56, 3.48, 2.77, 2.12, 1.97), one methoxy ($\delta_{\rm H}$ 4.03), one methylenedioxy ($\delta_{\rm H}$ 6.00) and six aromatic methynes ($\delta_{\rm H}$ 7.41, 7.32, 6.96, 6.87,6.79, 6.62). The ¹H spectrum of compound5 indicated that the H-3" ($\delta_{\rm H}$ 3.48) was shifted upfield compared to that of H-3" ($\delta_{\rm H}$ 3.73) of egonol (Table 1). This suggested that compound 5 contained an ether bond. The ¹³C NMR spectrum of 5 indicated a total of 22 carbons instead of 19 carbons, which is observed for egonol. Amongst the signals in the ¹³C NMR spectrum were those for six methylene carbons (δ_C 70.33, 68.28, 32.85, 31.95, 32.16, 30.95), one methoxy carbon ($\delta_{\rm C}$ 56.43), six aromatic methyne carbons (119.44, 112.62, 108.83, 107.83, 105.79, 100.61), one methylenedioxy carbon ($\delta_{\rm C}$ 101.53) and eight quaternary carbons (156.29, 148.28, 148.21, 144.99, 142.72, 137.85, 131.25, 125.02). The corresponding carbons bearing the different protons were identified from the HMQC spectrum. In the COSY spectrum, the methylene proton at $\delta_{\rm H}$ 2.12 ($\delta_{\rm C}$ 30.95) showed vicinal coupling with the methylene protons at $\delta_{\rm H}$ 3.56 (2H, m, $\delta_{\rm C}$ 68.28; 2H, m, $\delta_{\rm C}$ 31.95). The protons of another methylene $\delta_{\rm H}$ 1.97 ($\delta_{\rm C}$ 32.16) exhibited coupling with

Scheme 1. Synthesis of egonol derivatives (1–3, 5–8 and 10). Reagents and conditions: (a) *p*-toluenesulfonylchloride/pyridine; (b) NaBr/H₂SO₄ in water, reflux; (c) NBS/CCl₄, reflux; (d) PCC in CH₂Cl₂; (e) DMF–KOH in THF; (f) 1,3-dibromopropane, K₂CO₃/DMF; (g) benzoylchloride in THF, AlCl₃; (h) oleic acid/*p*-toluenesulfonylchloride in pyridine.

$$\begin{array}{c} OH \\ \\ OH \\ \\ OMe \\ \end{array}$$

$$\begin{array}{c} CI \\ \\ OMe \\ \end{array}$$

$$\begin{array}{c} CN \\ \\ OMe \\ \end{array}$$

$$\begin{array}{c} OH \\ OH \\ OH \\ \end{array}$$

Scheme 2. Synthesis of egonol derivatives (4, 9 and 11). Reagents and conditions: (a) *p*-toluensulfonylchloride/pyridine; (b) NaCN in DMSO, reflux; (c) NaI in acetone; (d) KNO₃, H₂SO₄.

the methylene protons at $\delta_{\rm H}$ 3.48 (2H, t, $\delta_{\rm C}$ 70.33) and $\delta_{\rm H}$ 2.77 (2H, t, $\delta_{\rm C}$ 32.85). Thus, compound5 was determined to be 5-[3-(3"-bromopropyloxy)propyl]-7-methoxy-2-(3', 4'-methylenedioxyphenyl)benzofuran.

Compound 6 was obtained from the reaction of egonol with KOH in DMF (Scheme 1) and gave a protonated ion peak at m/z 355.1 [M+H]⁺ by LCMS-APCI, which suggested a molecular formula of C₂₀H₁₈O₆. The ¹H NMR spectrum of compound 6 showed that the resonance of H-3" ($\delta_{\rm H}$ 4.23) was shifted downfield compared to that of H-3" of egonol ($\delta_{\rm H}$ 3.73). The ¹³C NMR spectrum of 6 exhibited 20 carbons instead of 19 carbons, which is observed for egonol (Table 2). The ¹³C NMR spectrum of compound 6 showed three methylene carbons (63.49, 32.56, 30.82), one methoxy carbon ($\delta_{\rm C}$ 56.44), six aromatic methyne carbons ($\delta_{\rm C}$ 100.57, 112.61, 107.71, 105.79, 108.84, 119.48), one methylenedioxy carbon (δ_C 101.53), eight quaternary carbons (156.43, 148.30, 148.26, 145.10, 142.83, 136.84, 131.38, 124.93), and one carbonyl carbon (161.29). Thus, compound 6 was determined to be 3-[2-(1,3-benzodioxol-5yl)-7-methoxy-1-benzofuran-5-yl\propylmethanoate.

Compound 7 was obtained from the reaction of oleic acid and egonol (Scheme 1). The 1 H NMR spectrum of compound 7 showed that the resonance of H-3" ($\delta_{\rm H}$ 4.14) was shifted downfield compared to that of H-3" of egonol ($\delta_{\rm H}$ 3.71, Table 1). LCMS/APCI gave ion peaks at m/z 590.4, 591.3, 589.3 [M] $^{+}$. The 13 C NMR spectrum exhibited a total of 37 carbons (Table 2). Comparison of the 1 H and 13 C NMR spectral assignments for H-3" and C3" of 7 revealed downfield shifts of +0.41 and 1.11 ppm, respectively, suggesting that the C3" was esterified in compound 7. Therefore, compound 7 was established as 3-[2-(1,3-benzodioxol-5-yl)-7-methoxy-1-benzofuran-5-yl]propyloleate.

Compound **8** was obtained from the reaction of egonol with NBS in CCl₄ (Scheme 1). The molecular formula of **8**was assigned as C₁₉H₁₆BrO₅ from the ion peaks at *m/z* 405.0 [M]⁺, 407.0 [M]⁺ in the LCMS/APCI. The ¹H NMR spectrum of compound **8** exhibited one methyl-

enedioxy ($\delta_{\rm H}$ 6.01), three methylenes ($\delta_{\rm H}$ 3.74, 2.88, 2.18), one methoxy ($\delta_{\rm H}$ 4.04) and five aromatic protons $(\delta_{\rm H}, 7.41, 7.31, 6.85 \, (2H), 6.67)$, and indicated the disappearance of the H6 signal. The ¹³C NMR spectra showed a total of 19 carbons, which included three methylenes (δ_C 62.39, 33.62, 32.32), one methoxy (δ_C 56.68), five aromatic methynes (δ_C 101.28, 109.15, 105.82,108.89, 119.71), one methylenedioxy ($\delta_{\rm C}$ 102.099) and nine quaternary aromatic carbons ($\delta_{\rm C}$ 156.68, 132.79, 136.18, 144.48, 142.13, 124.38, 148.57, 148.37, 105.70). The absence of a signal at $\delta_{\rm H}$ 6.66/ $\delta_{\rm C}$ 107.86 (H5 in egonol) and the presence of a signal at $\delta_{\rm C}$ 105.70 (instead at $\delta_{\rm C}$ 100.76 in egonol) confirmed the presence of a C5 bromo derivative. Further, the correlation between $\delta_{\rm C}$ 137.92/ $\delta_{\rm H}$ 6.66 in egonol was not observed in the HMQC spectrum of compound 8. Although NBS was used for benzylic bromination, ¹H, ¹³C, HMQC and HMBC NMR spectra indicated that the product was obtained by aromatic substitution (Scheme 1). Thus, compound 8 was identified as 5-[3''hydroxypropyl]-6-bromo-7-methoxy-2-(3',4'-methylenedioxyphenyl) benzofuran.

The reaction of compound 1 and NaCN in DMSO afforded compound 9 (Scheme 2). Its structure was confirmed by ¹H and ¹³C NMR spectra. The ¹H spectrum of compound 9 showed three methylene ($\delta_{\rm H}$ 2.83, 2.33, 2.02), one methoxy ($\delta_{\rm H}$ 4.03), one methylenedioxy ($\delta_{\rm H}$ 5.99) and six aromatic methyne ($\delta_{\rm H}$ 7.40, 7.32, 6.95, 6.87, 6.78, 6.60) protons. The $^{13}{\rm C}$ NMR spectrum showed a total of 20 carbons, which included three methylene carbons (δ_C 34.87, 27.53, 16.54), one methoxy carbon ($\delta_{\rm C}$ 56.68), one methylendioxy carbon ($\delta_{\rm C}$ 101.63), six aromatic methyne carbons ($\delta_{\rm C}$ 100.51, 112.78, 107.59, 105.82, 108.86, 119.51) and nine quaternary carbons (δ_C 156.59, 131.49, 135.60, 145.26, 142.97, 124.80, 148.34, 148.34, 119.81 (CN)). The ¹H and ¹³C NMR spectra of compound 9 showed that the resonances of H3" and C3" (δ 2.83; 16.54) were shifted upfield compared to that of H3" and C3" (δ 3.57; 46.46) of compound 1. Therefore, compound 9 was established as 4-[2-(1,3-benzodioxol-5-yl)-7-methoxy-1-benzofuran-5-yl]butanenitrile.

Table 1. 'H NMR of ego	Table 1. $^1\mathrm{H}$ NMR of egonol and its derivatives (CDCl ₃ , 400 MHz, 30 $^{\circ}\mathrm{C})$	7l ₃ , 400 MHz, 30 °C)									
	Egonol	1 δ ppm	2 δ ppm	3δ ppm	4 δ ppm	5 ∂ ppm	6 δ ppm	7 δ ppm	8 δ ppm	6 δ ppm	11 δ ppm
H3	6.81, s, 1H	6.77, s, 1H	6.77, s, 1H	6.77, s, 1H	6.79, s, 1H	6.79, s, 1H	6.78, s, 1H	6.78, s, 1H	6.67, s, 1H	6.78, s, 1H	
H4	6.99, s, 1H	6.96, s, 1H	6.96, s, 1H	6.96, s, 1H	6.88, s, 1H	6.96, s, 1H	6.95, d, 1H, $J = 1.6$ Hz	6.95, d, 1H, J = 1.6 Hz 6.85, s, 1H	6.85, s, 1H	6.95, s, 1H	7.56, s, 1H
H6	6.66, s, 1H	6.62, s, 1H	6.62, s, 1H, $J = 1.6$	6.62, d, 1H, J=1.6	6.62, d, 1H, J = 0.8	6.62, s, 1H	6.60, d, 1H, J = 1.2	6.61, d, 1H J=1.2	1	6.60, s, 1H	6.77, s, 1H
H2'	7.34, d, 1H, $J = 1.5$	7.32, d, 1H, $J = 4.0$	7.32, d, 1H, J=4.0	7.32, d, 1H, $J = 4.0$	7.32, d, 1H, $J = 1.6$	7.32, d, 1H	7.32, d, 1H, $J = 4.0$	7.32d, 1H, J = 1.6 Hz	7.31, d, 1H, J=3.8	7.32, d, 1H, $J = 1.2$	7.49, d, 1H, J = 1.6
H2,	6.90, d, 1H, J = 8.1	6.88, d, 1H, J = 8.0	6.88, d, 1H, J = 8.0	6.88, d, 1H, J = 8.0	6.88, d, 1H, J = 8.4	6.87, d, 1H, $J = 8.0$	6.87, d, 1H, $J = 8.0$	6.88, d, 1H, J = 8.4	6.85, d, 1H, J = 8.0	6.87, d, 1H, $J = 8.1$	6.94, d, 1H, J = 8.4
,9H	7.43, dd, 1H, J = 1.6, 8.1	7.41, dd, 1H, J = 8.0, 23	7.43, dd, 1H, J = 1.6, 81 7.41, dd, 1H, J = 8.0, 2.0 7.41, dd, 1H, J = 1.6, 80 7.41, dd, H, J = 1.6, 80 7.39, dd, H, J = 1.6, 80 7.40, dd, 1H, J = 1.6, 80 7.41, dd, H, J = 1.6, 8.0 7.41, dd, H, J = 1.	9 7.41, dd, H, J = 1.6, 8.0	7.39, dd, 1H, J=1.2, 7.8	7.41, dd, H, J = 1.6, 8.0	7.40, dd, 1H, J = 1.6, 8.0	7.41, dd, H, J = 1.6, 8.3	7.41, dd, 1H, J = 1.6, 8.0	7.40, dd, 1H, J = 1.2, 7.8	7.63, d, 1H, J= 1.6, 8.4
OCH_2O	6.02, s, 2H	6.00, s, 2H	6.00, s, 2H	6.00, s, 2H	6.00, s, 2H	6.00, s, 2H	6.00, s, 2H	5.99, s, 2H	6.02, s, 2H	5.99, s, 2H	6.01, s, 2H
OMe	4.05, s, 3H	4.04, s, 3H	4.04, s, 3H	4.04, s, 3H	4.04, s, 3H	4.03, s, 3H	4.03, s, 3H	4.03, s, 3H	4.04, s, 3H	4.03, s, 3H	4.01, s, 3H
H1"	2.81, t, 2H, J = 7.5, 7.8		2.86, t, 2H, J = 6.8, 7.6 2.86, t, 2H, J = 7.6, 7.2		2.85, t, 2H, J = 1.2, 6.8 2.79, t, 2H, J = 7.2, 7.2	2.77, t, 2H, J = 7.6, 7.6	2.77, t, 2H, J = 7.6, 7.6 2.78, t, 2H, J = 7.5, 7.7	2.76, m, 2H	2.88, t, 2H, J=7.5, 7.8	2.33, t, 2H, J = 7.2, 7.2	2.86, t, 2H, J = 7.2, 8.4
H2"	1.97, p, 2H	2.16, p, 2H	2.23, p, 2H	3.05, t, 2H, J = 8.0, 7.2 2.17, p, 2H	2.17, p, 2H	1.97, p, 2H	2.06, p, 2H	2.05m, 2H	2.18, p, 2H	2.02, p, 2H	2.00, p, 2H
H3,,	3.73, t, 2H, J = 6.4, 6.4	3.57, t, 2H, J = 6.8, 6.4	3.73, t, 2H, J = 6.4, 6.4 3.57, t, 2H, J = 6.8, 6.4 3.43, t, 1H, J = 6.8, 6.0 9.85, t, 1H, J = 0.8, 1.6 3.19, t, 2H, J = 7.2, 6.8	9.85, t, 1H, J = 0.8, 1.6	3.19, t, 2H, J = 7.2, 6.8		3.48, t, 2H, J = 6.8, 6.0 4.23, t, 2H, J = 6.4, 6.2	4.14, t, 2H, J = 6.8, 6.4	4.14, t, 2H, J = 6.8, 6.4 3.74, t, 2H, J = 4.0, 1.6	2.83, t, 2H, J = 7.6, 7.2 3.74, t, 2H, J = 6.4, 6.4	3.74, t, 2H, J = 6.4, 6.4
HC00-						8.09, s, 1H					
Bromo-propyloxyoleate	ate					3.56, m, 4H					
						2.12, p, 2H					
								5.36, 2H, m			
								2.76, 2H, m			
								2.32, 2H, t			
								J = 7.2, 7.2			
								2.05, 4H, m			
								1.63, m, 2H			
								1.31, 16H, br			
								s;0.89, t, 3H			

Compound 10, which was also isolated from *S. officinalis* L. as a minor compound, was obtained from the reaction of egonol with benzoylchloride and AlCl₃in THF (Scheme 1). Its structure was established by comparison of its ¹H NMR spectrum with literature data.¹

Compound 11 was obtained from the reaction of egonol with KNO₃ (Scheme 2). Its structure was established by ¹H, ¹³C, HMQC and HMBC NMR spectra. The ¹H NMR spectrum of compound 11 exhibited one methylenedioxy (δ 6.01), three methylene (δ 3.74, 2.86, 2.00), one methoxy (δ 4.01) and five aromatic protons (7.63, 7.63, 7.56, 7.49, 6.94, 6.77), and indicated the disappearance of the H3 signal. The ¹³C NMR spectra showed a total of 19 carbons, which included three methylenes ($\delta_{\rm C}$ 62.32, 34.82, 32.87), one methoxy (δ_C 56.43), five aromatic methynes (δ_C 125.77, 112.78, 109.68, 110.13, 108.61), one methylenedioxy (δ_C 102.099) and nine quaternary aromatic carbons ($\delta_{\rm C}$ 156.85, 123.71, 140.39, 141.06, 145.02, 145.02, 121.26, 150.79, 147.93). The absence of the signals at $\delta_{\rm H}$ 6.81/ $\delta_{\rm C}$ 100.76 (H3 in egonol) and the presence of a signal at $\delta_{\rm C}$ 123.71 (instead $\delta_{\rm C}$ 100.76 in egonol) confirmed the presence of a C3 nitro derivative. Further, the correlation between δ_C 100.76 and $\delta_{\rm H}$ 6.81 in the HMQC spectrum of egonol was not observed in the HMQC spectrum of compound 11, and HMQC spectrum of compound 11 indicated that mononitration was obtained at C3 (Tables 1 and 2). Therefore, the structure of compound 11 was assigned as 5-[3"-hydroxypropyl]-7-methoxy-3-nitro-2-(3',4'-methylenedioxyphenyl)benzofuran.

3. Conclusions

Egonol and synthesised compound were evaluated for antibacterial activity against *Staphylococcus aureus*, *Bacillus subtilis*, *Candida albicans* and *Escherichia coli* (Table 3). Compounds 4, 7, 8, 9, 10 showed antibacterial activity towards *S. aureus*, *B. subtilis*, *C. albicans* and *E. coli* that were similar to egonol. This indicated that substitution of hydroxyl with I or CN at C3"; esterification of hydroxyl at C3" with oleic acid or benzoic acid and aromatic substitution at C6 with Br or C3 with NO₃, did not result in increasing the activity of egonol. Only compounds 1, 3 and 6 showed noticeable activities against *S. aureus*, *B. subtilis*, *C. albicans* and *E. coli*. Compounds 2 and 5 showed partial activities. In conclusion, compounds 1–11 showed partial activities.

4. Antibacterial activities

Egonol (10 mg), compound 1 (10 mg), compound 2 (8.8 mg), compound 3 (10 mg), compound 4 (10 mg), compound 5 (8.9 mg), compound 6 (10 mg), compound 7 (10 mg), compound 8 (10 mg), compound 9 (10 mg), compound 10 (10 mg) and compound 11 (10 mg) were evaluated for antibacterial activity by using the Muller Hilton Broth (MHB) method with *S. aureus*, *B. subtilis*, *C. albicans* and *E. coli*. Stock solution of all compounds were dissolved in 1 ml methanol and 0.3 ml dicholorom-

Table 2. ¹³C NMR of compound 1, 4–9, 11 (CDCl₃, 100 MHz, 30 °C)

Egonol δ ppm	No.	1 δ ppm	4 δ ppm	5 δ ppm	6 δ ppm	7 δ ppm	8 δ ppm	9 δ ppm	11 <i>δ</i> ppm
156.51, q	C2	156.43	156.44	156.29	156.43	156.35	156.68	156.59	156.85
100.76, d	C3	100.56	100.56	100.61	100.57	100.58	101.28	100.51	123.71
131.46, q	C3a	131.38	131.37	131.25	131.38	131.31	132.79	131.49	140.39
112.72, q	C4	112.78	112.79	112.62	112.61	112.56	109.15	112.78	112.78
137.92, q	C5	136.58	136.28	137.85	136.84	137.72	136.18	135.60	141.06
107.86, d	C6	107.82	107.83	107.83	107.71	107.77	105.70	107.59	109.68
145.20.q	C7	145.27	145.10	144.99	145.10	145.05	144.48	145.26	145.02
142.88, q	C7a	142.84	145.10	142.72	142.83	142.75	142.13	142.97	145.02
125.12, q	C1′	124.92	124.91	125.02	124.93	124.98	124.38	124.80	121.26
105.95, d	C2'	105.78	105.79	105.79	105.79	105.79	105.82	105.82	110.13
148.46, q	C3′	148.32	148.31	148.28	148.30	148.29	148.57	148.34	150.79
148.39, q	C4'	148.27	148.27	148.21	148.26	148.22	148.37	148.34	147.93
109.02, d	C5′	108.84	108.85	108.83	108.84	108.83	108.89	108.86	108.61
119.62, d	C6′	119.47	119.47	119.44	119.48	119.46	119.71	119.51	125.77
32.83, t	C1"	33.27	36.67	31.95	30.82	30.98	32.32	34.87	34.82
35.08, t	C2"	34.68	35.50	32.16	32.56	32.76	33.62	27.53	32.87
62.70, t	C3"	44.46	6.72	68.28	63.49	63.81	62.39	16.54	62.32
56.57, s	OMe	56.4	56.45	56.43	56.44	56.48	56.68	56.48	56.43
101.71, t	OCH_2O	101.53	101.54	101.54	101.53	101.52	101.63	101.57	102.09
	Bromo-pro	pyloxy		70.33, 30.9	5				
	CN			ŕ				119.81	
	C=O				161.29	179.26			
	Oleate					130.23 (2C), 34.68, 25.24	, 28.32(8C), 2°	7.42 (2C),
						31.74, 22.8			

Table 3. Antibacterial activity of compound egonol and 1-11

Compounds	S. aureus ^a	B. subtilus ^a	C. albicans ^a	E. coli ^a
Egonol	800	800	800	800
1	256	128	64	256
2	800	400	400	800
3	64	256	128	800
4	800	800	800	800
5	256	256	800	800
6	400	400	400	400
7	800	800	800	800
8	800	800	800	800
9	800	800	*	800
10	800	800	800	800
11	*	800	800	*

^{*}Not active.

ethane separately and prepareted 1/2 Muller Hilton Broth (MHB) solution.

5. Experimental

5.1. General

The 1D NMR and 2D NMR spectra were measured in CDCl₃ at 400 MHz for ¹H NMR and 100 MHz for ¹³C NMR on a Varian AS-400 spectrometer. LCMS was recorded on a AGILENT 1100MSD spectrometer and FABMS was obtained using a zapSpec FAB (+) spectrometer. CC and PTLC were carried out on Si gel 60 (Merck 7734) and Merck 5554. TLC was carried out on Alugram (Sil G/UV 254, Merck 5554) using sulfuric acid at 120 °C.

5.2. Plant material

Fruits of *S. officinalis* L. were collected in September 2005 from Ephesus (Aydın, Turkey). A voucher specimen has been deposited in the herbarium of the Botanic Garden of Ege University.

5.3. Extraction

The shade dried and pulverised seed (241 g) of *S. officinalis* L. was exhaustively extracted with a *n*-hexane at room temperature. After removal of the solvent in vacuo, a crude yellow oily extract (113.72 g) was obtained. The hexane extract was hydrolysed with 33% KOH at 100 °C for 3 h. The reaction mixture was cooled at room temperature and extracted with CH₂Cl₂. The mixture was purified by CC using silica gel (Merck 7734) and CH₂Cl₂ as eluent to afford egonol (6 g), which was identified by ¹H and ¹³C NMR.

5.4. Egonol

5-[3"-(hydroxy)propyl]-7-methoxy-2-(3',4'-methylenedioxyphenyl)benzofuran. White powder. ¹H and ¹³C NMR (Tables 1 and 2).

5.5. Synthesis

5.5.1. 5-(3"-Chloropropyl)-7-methoxy-2-(3',4'-methylene-dioxyphenyl) benzofuran (1), amorphous solid. To a mixture of egonol (472 mg, 1.45×10^{-3} mol) in pyridine (9 ml) was added *p*-toluenesulfonylchloride (286 mg, 2.61×10^{-3} mol) at room temperature and the mixture was stirred for 72 h. The reaction mixture was diluted with water (15 ml) and extracted with CH₂Cl₂ (3×

^a MIC (μg/ml) = minimum inhibition concentration.

- 5 ml). The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness. The residue was purified by PTLC (CH₂Cl₂). 33.2 mg compound was obtained (6.66%). Mp 120.0–121.7 °C. UV λ_{max} CH₂Cl₂: 229, 318 nm. IR spectrum ν_{max} CH₂Cl₂ cm⁻¹: 2919, 1615, 1596, 1443, 1229, 1033, 930, 847. ¹H and ¹³C NMR: see Tables 1 and 2. LCMS/APCI m/z (rel. int.): 347.1 [M]⁺ ((5.9), 345.1 [M]⁺ (16.4), 282 [M–Cl–CH₂–CH₂)]⁺ (100), 283 [M–(Cl–CH₂–CH₂)+H]⁺ (24.1).
- **5.5.2.** 5-(3"-Bromopropyl)-7-methoxy-2-(3',4'-methylene-dioxyphenyl) benzofuran (2), viscous syrup. Concentrated $\rm H_2SO_4$ (1.3 ml) was added slowly to egonol (50 mg, 1.53×10^{-4} mol) in $\rm CH_2Cl_2$ (10 ml), followed by a slow addition of NaBr (15.8 mg) in 2 ml water. The mixture was then refluxed for 2 h. The reaction mixture was diluted with water (15 ml) and extracted with $\rm CH_2Cl_2$ (3×5 ml). The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated to dryness. The residue was purified by PTLC using $\rm CH_2Cl_2$ as a solvent. 8.8 mg compound was obtained (12.80%). $\lambda_{\rm max}$ $\rm CH_2Cl_2$: 229, 318 nm. IR spectrum $\nu_{\rm max}$ $\rm CH_2Cl_2$ cm $^{-1}$: 2917, 1596, 1473, 1360, 1229, 1146, 1039, 927, 760, 746. UV. $^1\rm H$ NMR (Table 1). LCMS/APCI m/z (rel. int.): 391.0 [M]⁺ (100), 389.0 [M]⁺ (97.4), 309 [M-Br]⁺ (22.9).
- **5.5.3.** 3-[2-(1,3-Benzodioxol-5-yl)-7-methoxy-1-benzofuran-5-yl|propanal (3), viscous syrup. A mixture of egonol (50 mg, 1.53×10^{-4} mol) and acetone: CH₂Cl₂ (3:3 ml) was stirred at room temperature. PCC (146 mg) and molecular sieves (4A, 544 mg) were added in several portions and the mixture was stirred at room temperature for 24 h. Subsequently, the mixture was diluted with water (15 ml) and extracted with CH₂Cl₂ (3× 5 ml). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified on silica gel using hexane/EtOAc/H₂O: 6:4:0,5 as eluent to give the product (12.9 mg, 26.02%). UV $\lambda_{\rm max}$ CH₂Cl₂: 231, 318 nm. IR spectrum $\nu_{\rm max}$ CH₂Cl₂ cm⁻¹: 2921, 2852, 1709, 1473, 1363, 1222, 1033, 927, 749. ¹H NMR (Table 1). LCMS/APCI m/z (rel. int.): 323.1 [M-H]⁺(1.9), 282.2 [M-CH₂CO]⁺ (100).
- **5.5.4.** 5-(3"-Iodopropyl)-7-methoxy-2-(3',4'-methylenedioxyphenyl) benzofuran (4), amorphous solid. To a mixture of compound 1 (40 mg, 1.16×10^{-4} mol) in acetone (5 ml) was added NaI (81 mg) with acetone (20 ml) in several portions at room temperature and the mixture was stirred for 120 h. The reaction mixture was diluted with water (15 ml) and extracted with CH₂Cl₂ (3× 5 ml). The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness. 39 mg compound was obtained (100.36%). Mp 117.8–118.9 °C UV $\lambda_{\rm max}$ CH₂Cl₂: 230, 319 nm. IR spectrum $\nu_{\rm max}$ CH₂Cl₂ cm⁻¹: 2906, 1722, 1622, 1497, 1475, 1363, 1231, 1031, 930, 740. ¹H and ¹³C NMR (Tables 1 and 2). LCMS/APCI m/z (rel. int.): 437.0 [M+H]⁺(28.1), 438.0 [M+H]⁺ (6), 325.1 [M-I]⁺ (30.2), 307.1 (100.0).
- 5.5.5. 5-[3-(7"-Bromopropyloxy)propyl]-7-mehtoxy-2-(3',4'-methylenedioxyphenyl)benzofuran (5), amorphous solid. Egonol (100 mg, 3.07×10^{-4} mol) was added to a mixture of 1,3-dibromopropane (2 ml) and K_2CO_3

- (500 mg) in DMF (5 ml). The mixture was stirred at room temperature for 72 h. It was diluted with CH_2Cl_2 (10 ml) and washed with water (3× 5 ml). The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness. The residue was purified by PTLC (CH_2Cl_2) and 6.1 mg brown oily compound was obtained (4.46%). Mp 63.7–65.0 °C. UV λ_{max} CH_2Cl_2 : 229, 318 mm. IR spectrum ν_{max} CH_2Cl_2 cm⁻¹: 2916, 2846, 1476, 1261, 1229, 1141, 1113, 1039, 950, 749. ¹H and ¹³C NMR (Tables 1 and 2). LCMS/APCI m/z (rel. int.): 449.1 [M]⁺ (100.0), 447.1 [M]⁺ (96.9), 367.2 [(M–Br)+H]⁺ (16.6), 355 [M–(CH_2 –Br)+H]⁺ (9.1), 327 [M–(Br– CH_2 – CH_2 – CH_2)+H]⁺ (8.7).
- **5.5.6.** 3-[2-(1,3-Benzodioxol-5-yl)-7-methoxy-1-benzofuran-5-yl]propylmethanoate (6), amorphous solid. A mixture of egonol (100 mg, 3.07×10^{-4} mol) and KOH (100 mg) in DMF (5 ml) was refluxed with stirring for 1 h. The reaction mixture was diluted with water (10 ml) and extracted with CH₂Cl₂ (3× 5 ml). The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness. The residue was purified by PTLC using CH₂Cl₂ as a solvent to give the product as a white solid (20.6 mg, 18.97%). Mp 77.8–78.2 °C. UV $\lambda_{\rm max}$ CH₂Cl₂: 229, 318 mm. IR spectrum $\nu_{\rm max}$ CH₂Cl₂ cm⁻¹: 2929, 2846, 1717, 1615, 1475, 1448, 1274, 1229, 1115, 1034, 921, 749, 710. ¹H and ¹³C NMR (Tables 1 and 2). LCMS/APCI m/z (rel. int.): 355.1 [M+H]⁺ (100), 356.1 [M+2H]⁺ (22.1), 327.1 [(M+2H)-CHO]⁺ (53.7).
- 5.5.7. 3-[2-(1,3-Benzodioxol-5-yl)-7-methoxy-1-benzofuran-5-yllpropyloleate (7), oily compound. To a stirred solution of egonol (472 mg, $1.45 \times \bar{10}^{-3}$ mol) in pyridine (9 ml) was added oleic acid in CH₂Cl₂ (800 mg, 2.83×10^{-3} mol). The reaction mixture was refluxed for 8 h and was stirred for a further 72 h at room temperature. The reaction mixture was diluted with water (15 ml) and extracted with CH₂Cl₂ (3× 5 ml). The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness. The residue was purified by PTLC using CH₂Cl₂ as a solvent. 47.6 mg white solid compound was obtained (5.57%). UV λ_{max} CH₂Cl₂: 230, 318 nm. IR spectrum ν_{max} CH₂Cl₂ cm⁻¹: 2924, 2846, 1721, 1618, 1600, 1476, 1363, 1232, 1146, 1038, 929, 814, 735. ¹H and ¹³C NMR (Tables 1 and 2). LCMS/APCI m/z (rel. int.): 589.3 [M-H]⁺ (6.0), 590.4 $[M]^+(3.0)$, 591.3 $[M+H]^+(4.5)$, 282 (100).
- 5.5.8. 5-[3"-Hydroxypropyl]-6-bromo-7-methoxy-2-(3',4'-methylenedioxyphenyl)benzofuran (8), brown amorphous solid. A mixture of egonol (100 mg, 3.07×10^{-4} mol), NBS (48 mg, 2.70×10^{-4} mmol), 3-chloroperoxybenzoic acid (10 mg, 5.79×10^{-5} mol) in CCl₄ (5 ml) was refluxed for 1 h. The reaction mixture was stirred at room temperature for 15 h. After addition of 10 ml water, the mixture was extracted with CH₂Cl₂ (3× 5 ml). The CH₂Cl₂ was dried with anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by PTLC using dichloromethane/methanol (80:4) as solvent system to give the product as a light brown solid (102 mg, 82.32%). Mp 137.3–145.0 °C. UV λ_{max} CH₂Cl₂: 229, 322 nm. IR spectrum ν_{max} CH₂Cl₂ cm⁻¹: 3296, 2925, 2857, 1733, 1599, 1476, 1363, 1232, 1141,

1039, 930, 749. 1 H and 13 C NMR (Tables 1 and 2). LCMS/APCI m/z (rel. int.): 405.0 [M] $^{+}$ (100), 407.0 [M] $^{+}$ (93.7), 326.1 [M-Br] $^{+}$ (46.8), [(M-Br)+H] $^{+}$ 327.1 (32.0).

5.5.9. 4-[2-(1,3-Benzodioxol-5-yl)-7-methoxy-1-benzofuran-5-yllbutanenitrile (9), amorphous solid. Sodium cyanide $(10 \text{ mg}, 2.09 \times 10^{-4} \text{ mol})$ was dissolved in anhydrous dimethyl sulfoxide at 90 °C. Then compound 1 (50 mg, 1.39×10^{-4} mol) in DMSO was added in several portions. The mixture was stirred at room temperature for 1 day. After addition of 15 ml water, the mixture was extracted with CH₂Cl₂ (3× 15 ml). The CH₂Cl₂ was dried with anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by PTLC using hexane/EtOAc/H₂O: 6:4:0.5 as a solvent to give the product as a yellow solid (48 mg, 103.08%). Mp 143.7–144.6 °C. UV λ_{max} CH₂Cl₂: 229,318 nm. IR spectrum ν_{max} CH₂Cl₂ cm⁻¹: 2935, 2245, 1599, 1448, 1365, 1232, 1144, 1115, 1038, 929, 817. 742. ¹H NMR and ¹³C NMR (Tables 1 and 2). LCMS/APCI m/z (rel. int.): 336.1 [M+H]⁺ (68.1), 309.1 [M-CN]⁺ (22.0), 308.1 (100.0), 278.1 (18.5).

5.5.10. 3-[2-(1,3-Benzodioxol-5-yl)-7-methoxy-1-benzofuran-5-yl]propylbenzoate (10), amorphous solid. A mixture of AlCl₃ (30 mg), THF (7 ml) and benzoylchloride (28 mg, 1.99×10^{-3} mol) was stirred at ice bath temperature. Egonol (50 mg, 1.53×10^{-4} mol) in THF was added in several portions and the mixture was stirred at room temperature for 2 h. The mixture was poured into an ice-water mixture and extracted with CH₂Cl₂ (4× 5 ml). The extract was dried with anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified via column chromatography on silica gel using hexane/EtOAc: 15:1 as eluent to afford the product as a white solid (19.5 mg, 29.64%). Mp 71.9–74.5 °C UV $\lambda_{\rm max}$ CH₂Cl₂: 231, 318 nm. IR spectrum $\nu_{\rm max}$ CH₂Cl₂ cm⁻¹: 2921, 1721, 1476, 1363, 1232, 1054, 1033, 930, 749. FABMS m/z (rel. int.): 430.0 [M]⁺ (2), 405.1 (20), 391.1 (100), 149.9 (75).

5.5.11. 5-[3"-Hydroxypropyl]-7-methoxy-3-nitro-2-(3',4'-methylenedioxyphenyl)benzofuran (11), yellow amorphous solid. Powdered KNO₃ (5.05×10^3 mg, 0.050 mol) was treated with the appropriate amount of 96% H₂SO₄ (1 ml) and the mixture was stirred for 15 min at room temperature; CH₂Cl₂ (25 ml) was added

to the homogeneous slurry so obtained and the mixture was cooled at 0 °C with vigorous stirring. A solution of egonol (50 mg, 1.53×10^{-4} mol) in CH₂Cl₂ was added dropwise and the stirring was continued at room temperature for the required time. The reaction mixture was then poured into 10% aqueous Na₂SO₄ and the separated organic phase was washed with 10% aqueous Na₂SO₄, dried over anhydrous Na₂SO₄, concentrated to dryness to afford the product⁷ (46 mg, 81%).

Mp 140.7–142.7 °C. UV $\lambda_{\rm max}$ CH₂Cl₂: 228, 268, 384 nm. IR spectrum $\nu_{\rm max}$ CH₂Cl₂ cm⁻¹:3379, 2922, 2851, 2483, 2132, 1605, 1473, 1338, 1056, 1033, 765, 743. ¹H and ¹³C NMR (Tables 1 and 2). LCMS/APCI m/z (rel. int.): 372.1 [M+H]⁺ (14.2), 282.2 (100.0).

Acknowledgments

This work was supported by a Grant 105T226 from TUBITAK. The authors thank Assoc. Prof. Stephan Thomas ASTLEY for proofing the manuscript.

References and notes

- 1. Akgul, Y. Y.; Anil, H. Phytochemistry 2003, 63, 939-943.
- 2. Anil, H. Phytochemistry 1980, 19, 2784–2786.
- 3. Byung-Sun, Min; Sei-Ryang, Oh; Kyung-Seop, Ahn; Jung-Hee, Kim; Joongku, Lee; Doo-Young, Kim; Eun-Hee, Kim; Hyeong-Kyu, Lee *Planta Med.* **2004**, *70*, 1210–1215.
- 4. Davis, P. H.. In *Flora of Turkey and the East Aegean Islands*; Edinburg University: Edinburg, 1972; Vol. 4, p 144.
- Kyung-Jin, Yun; Byung-Sun, Min; Ji-Yeon, Kim; Kyung-Tae, Lee Biol. Pharm. Bull. 2007, 30, 139–144.
- Pauletti, P. M.; Araujo, A. R; Young, M. C. M.; Giesbrecht, A. M.; Bolzani, V. Phytochemistry 2000, 55, 597–601.
- Strazzolini, Paolo; Giumanini, Angelo G.; Runcio, Antonio Tetrahedron Lett. 2001, 42, 1387–1389.
- 8. Toshihiko, Hirano; Manabu, Gotoh; Kitaro, Oka *Life Sci.* **1994**, *55*, 1061–1069.
- 9. Qi-Lin, Li; Bo-Gang, Li; Hua-Yi, Qi; Xiao-Ping, Gao; Guo-Lin, Zhang *Planta Med.* **2005**, *71*, 847–851.
- Vardar, Y.; Oflas, S. Qual. Plant. Mater. Veg. 1973, XXII, 145–148.
- 11. Yinggang, Luo; Zhiheng, He; Hongjuan, Li *Fitoterapia* **2007**, *78*, 211–214.